JANUARY – FEBRUARY 2026 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
CHMP January 29. Niraparib + Abiraterone acetate – mHSPC BRCA1/2 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending a new indication for the dual-action tablet: niraparib/abiraterone acetate is indicated with prednisone or prednisolone in combination with androgen deprivation therapy (ADT) for the treatment […]